The Ebola Epidemic Crystallizes the Potential of Passive Antibody Therapy for Infectious Diseases

Overview

Journal PLoS Pathog

Specialty Microbiology

Date 2015 Apr 24

PMID 25905897

Citations 18

Authors

Arturo Casadevall

Liise-Anne Pirofski

Affiliations

Soon will be listed here.

Citing Articles

Diverse Effects of Exosomes on COVID-19: A Perspective of Progress From Transmission to Therapeutic Developments.

Gurunathan S, Kang M, Kim J Front Immunol. 2021; 12:716407.

PMID: 34394121 PMC: 8355618. DOI: 10.3389/fimmu.2021.716407.

Unleashing the potential of cell membrane-based nanoparticles for COVID-19 treatment and vaccination.

Pereira-Silva M, Chauhan G, Shin M, Hoskins C, Madou M, Martinez-Chapa S Expert Opin Drug Deliv. 2021; 18(10):1395-1414.

PMID: 33944644 PMC: 8182831. DOI: 10.1080/17425247.2021.1922387.

Quantum leap of monoclonal antibody (mAb) discovery and development in the COVID-19 era.

Pecetta S, Finco O, Seubert A Semin Immunol. 2020; 50:101427.

PMID: 33277154 PMC: 7670927. DOI: 10.1016/j.smim.2020.101427.

SARS-CoV-2/COVID-19 and advances in developing potential therapeutics and vaccines to counter this emerging pandemic.

Rabaan A, Al-Ahmed S, Sah R, Tiwari R, Yatoo M, Patel S Ann Clin Microbiol Antimicrob. 2020; 19(1):40.

PMID: 32878641 PMC: 7464065. DOI: 10.1186/s12941-020-00384-w.

Advances and challenges in the prevention and treatment of COVID-19.

Han Y, Ren Z, Li X, Yan J, Ma C, Wu D Int J Med Sci. 2020; 17(12):1803-1810.

PMID: 32714083 PMC: 7378666. DOI: 10.7150/ijms.47836.

References

. Update: ebola virus disease epidemic - West Africa, December 2014. MMWR Morb Mortal Wkly Rep. 2014; 63(50):1199-201. PMC: 5779527. View

Butler D . Ebola raises profile of blood-based therapy. Nature. 2015; 517(7532):9-10. DOI: 10.1038/517009a. View

MacNeil A, Reed Z, Rollin P . Serologic cross-reactivity of human IgM and IgG antibodies to five species of Ebola virus. PLoS Negl Trop Dis. 2011; 5(6):e1175. PMC: 3110169. DOI: 10.1371/journal.pntd.0001175. View

Burton D, Poignard P, Stanfield R, Wilson I . Broadly neutralizing antibodies present new prospects to counter highly antigenically diverse viruses. Science. 2012; 337(6091):183-6. PMC: 3600854. DOI: 10.1126/science.1225416. View

Wang T, Tan G, Hai R, Pica N, Petersen E, Moran T . Broadly protective monoclonal antibodies against H3 influenza viruses following sequential immunization with different hemagglutinins. PLoS Pathog. 2010; 6(2):e1000796. PMC: 2829068. DOI: 10.1371/journal.ppat.1000796. View

Lowy I, Molrine D, Leav B, Blair B, Baxter R, Gerding D . Treatment with monoclonal antibodies against Clostridium difficile toxins. N Engl J Med. 2010; 362(3):197-205. DOI: 10.1056/NEJMoa0907635. View

Mupapa K, Massamba M, Kibadi K, Kuvula K, Bwaka A, Kipasa M . Treatment of Ebola hemorrhagic fever with blood transfusions from convalescent patients. International Scientific and Technical Committee. J Infect Dis. 1999; 179 Suppl 1:S18-23. DOI: 10.1086/514298. View

Sobarzo A, Groseth A, Dolnik O, Becker S, Lutwama J, Perelman E . Profile and persistence of the virus-specific neutralizing humoral immune response in human survivors of Sudan ebolavirus (Gulu). J Infect Dis. 2013; 208(2):299-309. DOI: 10.1093/infdis/jit162. View

Bournazos S, Klein F, Pietzsch J, Seaman M, Nussenzweig M, Ravetch J . Broadly neutralizing anti-HIV-1 antibodies require Fc effector functions for in vivo activity. Cell. 2014; 158(6):1243-1253. PMC: 4167398. DOI: 10.1016/j.cell.2014.08.023. View

10.

Rybicki E . Plant-based vaccines against viruses. Virol J. 2014; 11:205. PMC: 4264547. DOI: 10.1186/s12985-014-0205-0. View

11.

Fedson D . A practical treatment for patients with Ebola virus disease. J Infect Dis. 2014; 211(4):661-2. DOI: 10.1093/infdis/jiu474. View

12.

Rouvinski A, Guardado-Calvo P, Barba-Spaeth G, Duquerroy S, Vaney M, Kikuti C . Recognition determinants of broadly neutralizing human antibodies against dengue viruses. Nature. 2015; 520(7545):109-13. DOI: 10.1038/nature14130. View

13.

Bakker A, Python C, Kissling C, Pandya P, Marissen W, Brink M . First administration to humans of a monoclonal antibody cocktail against rabies virus: safety, tolerability, and neutralizing activity. Vaccine. 2008; 26(47):5922-7. DOI: 10.1016/j.vaccine.2008.08.050. View

14.

Almansa R, Eiros J, Fedson D, Bermejo-Martin J . Hyperimmune serum from healthy vaccinated individuals for Ebola virus disease?. Lancet Glob Health. 2014; 2(12):e686. DOI: 10.1016/S2214-109X(14)70341-9. View

15.

Casadevall A, Pirofski L . Antibody-mediated regulation of cellular immunity and the inflammatory response. Trends Immunol. 2003; 24(9):474-8. DOI: 10.1016/s1471-4906(03)00228-x. View

16.

Greenough T, Babcock G, Roberts A, Hernandez H, Thomas Jr W, Coccia J . Development and characterization of a severe acute respiratory syndrome-associated coronavirus-neutralizing human monoclonal antibody that provides effective immunoprophylaxis in mice. J Infect Dis. 2005; 191(4):507-14. PMC: 7110081. DOI: 10.1086/427242. View

17.

Reichert J . Which are the antibodies to watch in 2013?. MAbs. 2012; 5(1):1-4. PMC: 3564874. DOI: 10.4161/mabs.22976. View

18.

Casadevall A, Pirofski L . A new synthesis for antibody-mediated immunity. Nat Immunol. 2011; 13(1):21-8. PMC: 3589717. DOI: 10.1038/ni.2184. View

19.

Casadevall A, Scharff M . Return to the past: the case for antibody-based therapies in infectious diseases. Clin Infect Dis. 1995; 21(1):150-61. PMC: 7197598. DOI: 10.1093/clinids/21.1.150. View

20.

Luke T, Casadevall A, Watowich S, Hoffman S, Beigel J, Burgess T . Hark back: passive immunotherapy for influenza and other serious infections. Crit Care Med. 2010; 38(4 Suppl):e66-73. DOI: 10.1097/CCM.0b013e3181d44c1e. View